{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:54:00Z","timestamp":1784876040528,"version":"3.55.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>McCune\u2013Albright syndrome (MAS) is a rare mosaic genetic disorder caused by a mutation in the GNAS gene and typically presents with a triad of symptoms: fibrous dysplasia of bones, caf\u00e9-au-lait macules, and precocious puberty. The GNAS mutation leads to overproduction of fibroblast growth factor-23 (FGF23), which may result in hypophosphatemia. Burosumab, a monoclonal antibody against FGF23, is approved for the treatment X-linked hypophosphatemia and tumor-induced osteomalacia. There are currently no data on its efficacy and safety in fibrous dysplasia\/MAS patients. A 27-yr-old male with MAS was under the care of the Endocrinology Department for persistent hypophosphatemia and skeletal complications despite treatment with oral phosphate supplements and calcitriol. He started treatment with burosumab (1\u00a0mg\/kg\u00a0s.c. every 4\u00a0wk) and achieved normalization of calcium\u2013phosphate metabolism (phosphate 0.83\u00a0mmol\/L vs 0.38\u00a0mmol\/L; PTH 70.4\u00a0pg\/mL vs 177\u00a0pg\/mL) and significant reduction in alkaline phosphatase activity (ALP 620\u00a0IU\/L vs 1182\u00a0IU\/L) and bone fraction of alkaline phosphatase activity (BALP 327\u00a0IU\/L vs 603\u00a0IU\/L). No further fractures were observed during 24\u00a0mo of treatment. The patient reported a reduction in bone pain and improved well-being. No adverse effects were reported during treatment. This is the first reported case of burosumab treatment in an adult patient with fibrous dysplasia\/MAS. The therapy had positive effects on the patient\u2019s well-being, calcium\u2013phosphate balance, and bone markers. However, longer follow-up and further safety studies are needed before routine use in adult fibrous dysplasia\/MAS patients.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf125","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T11:56:21Z","timestamp":1753444581000},"source":"Crossref","is-referenced-by-count":4,"title":["Burosumab treatment for fibroblast growth factor-23-associated hypophosphatemia in an adult patient with severe fibrous dysplasia in McCune\u2013Albright syndrome: case report and review of the literature"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2961-3316","authenticated-orcid":false,"given":"Maria","family":"Stelmachowska-Bana\u015b","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Centre of Postgraduate Medical Education , 01-813 Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Cylke-Falkowska","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Centre of Postgraduate Medical Education , 01-813 Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Zgliczy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Centre of Postgraduate Medical Education , 01-813 Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Bilezikian","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Vagelos College of Physicians and Surgeons, Columbia University , New York, NY 10032 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Misiorowski","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Centre of Postgraduate Medical Education , 01-813 Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"1","key":"2025082100520292600_ref1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1172-3-12","article-title":"McCune-Albright syndrome","volume":"3","author":"Dumitrescu","year":"2008","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2025082100520292600_ref2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s11914-016-0317-0","article-title":"Fibrous dysplasia\/McCune-Albright syndrome: clinical and translational perspectives","volume":"14","author":"Robinson","year":"2016","journal-title":"Curr Osteoporos Rep"},{"issue":"6","key":"2025082100520292600_ref3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000504802","article-title":"The clinical spectrum of McCune-Albright syndrome and its management","volume":"92","author":"Spencer","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2025082100520292600_ref4","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnz011","article-title":"Fibrous dysplasia\/McCune-Albright syndrome: a rare, mosaic disease of Galpha s activation","volume":"41","author":"Boyce","year":"2020","journal-title":"Endocr Rev"},{"key":"2025082100520292600_ref5","doi-asserted-by":"crossref","first-page":"1-14, e230242","DOI":"10.20945\/2359-4292-2023-0242","article-title":"Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: a systematic review","volume":"68","author":"Dodamani","year":"2024","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"2025082100520292600_ref6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000527129","article-title":"Burosumab therapy in a paediatric patient with McCune-Albright syndrome: a case report","volume":"96","author":"Apperley","year":"2023","journal-title":"Horm Res Paediatr"},{"key":"2025082100520292600_ref7","doi-asserted-by":"publisher","first-page":"116004","DOI":"10.1016\/j.bone.2021.116004","article-title":"Burosumab treatment for fibrous dysplasia","volume":"150","author":"Gladding","year":"2021","journal-title":"Bone"},{"issue":"3","key":"2025082100520292600_ref8","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.CC.24.00279","article-title":"Improvement of fibrous dysplasia after burosumab therapy in a pediatric patient with McCune-Albright syndrome: a case report","volume":"14","author":"Sawamura","year":"2024","journal-title":"JBJS Case Connect"},{"key":"2025082100520292600_ref9","doi-asserted-by":"crossref","first-page":"1577734","DOI":"10.3389\/fendo.2025.1577734","article-title":"Use of burosumab in McCune Albright syndrome: case report and review of literature in mosaic disorders with FGF23 overproduction","volume":"16","author":"Barbato","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2025082100520292600_ref10","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1002\/jbmr.3531","article-title":"Chiari I malformation and basilar invagination in fibrous dysplasia: prevalence, mechanisms, and clinical implications","volume":"33","author":"Pan","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025082100520292600_ref11","doi-asserted-by":"publisher","first-page":"E126","DOI":"10.1210\/jc.2012-2111","article-title":"Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess","volume":"98","author":"Boyce","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025082100520292600_ref12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/jbmr.1546","article-title":"Mechanism of FGF23 processing in fibrous dysplasia","volume":"27","author":"Bhattacharyya","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2025082100520292600_ref13","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2025082100520292600_ref14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1172\/JCI18399","article-title":"FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting","volume":"112","author":"Riminucci","year":"2003","journal-title":"J Clin Invest"},{"issue":"4","key":"2025082100520292600_ref15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1359\/jbmr.070107","article-title":"FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets","volume":"22","author":"Imel","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025082100520292600_ref16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/jcph.611","article-title":"Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia","volume":"56","author":"Zhang","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"2025082100520292600_ref17","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1210\/jc.2014-1371","article-title":"A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone","volume":"99","author":"Boyce","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025082100520292600_ref18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1056\/NEJMc2214862","article-title":"Safety and efficacy of denosumab for fibrous dysplasia of bone","volume":"388","author":"de Castro","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"2025082100520292600_ref19","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/jbmr.4380","article-title":"Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study","volume":"36","author":"Meier","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025082100520292600_ref20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"2025082100520292600_ref21","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf125\/63845090\/ziaf125.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/9\/ziaf125\/63845090\/ziaf125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/9\/ziaf125\/63845090\/ziaf125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:52:07Z","timestamp":1755751927000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf125\/8212267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf125","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,25]]},"article-number":"ziaf125"}}